BrainsWay Advances TMS Treatment Coverage Policy Changes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy BWAY?
Source: Newsfilter
- Policy Update: In late 2025, Optum/United Behavioral Health updated its TMS clinical policy to allow psychiatric mental health nurse practitioners to administer TMS therapy in states granting full practice authority, covering approximately 34.8 million lives and significantly broadening the pool of qualified clinicians.
- Market Demand: With the increasing shortage of psychiatrists in the U.S., BrainsWay believes that expanding the role of nurse practitioners in TMS therapy will improve patient access and reduce wait times, enabling more patients to benefit from clinically proven non-pharmacologic treatment options.
- Broad Support: In addition to Optum, multiple U.S. commercial payers and government payers, including the Department of Veterans Affairs and TRICARE West, have adopted similar coverage policies, further enhancing the role of nurse practitioners in TMS care while complying with applicable policy and regulatory frameworks.
- Technological Advantage: BrainsWay's Deep TMS™ platform technology has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, with ongoing clinical trials reinforcing its leadership position in the mental health sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BWAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BWAY
Wall Street analysts forecast BWAY stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.810
Low
19.00
Averages
26.33
High
30.00
Current: 15.810
Low
19.00
Averages
26.33
High
30.00
About BWAY
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BrainsWay Advances TMS Treatment Coverage Policy Changes
- Policy Update: In late 2025, Optum/United Behavioral Health updated its TMS clinical policy to allow psychiatric mental health nurse practitioners to administer TMS therapy in states granting full practice authority, covering approximately 34.8 million lives and significantly broadening the pool of qualified clinicians.
- Market Demand: With the increasing shortage of psychiatrists in the U.S., BrainsWay believes that expanding the role of nurse practitioners in TMS therapy will improve patient access and reduce wait times, enabling more patients to benefit from clinically proven non-pharmacologic treatment options.
- Broad Support: In addition to Optum, multiple U.S. commercial payers and government payers, including the Department of Veterans Affairs and TRICARE West, have adopted similar coverage policies, further enhancing the role of nurse practitioners in TMS care while complying with applicable policy and regulatory frameworks.
- Technological Advantage: BrainsWay's Deep TMS™ platform technology has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, with ongoing clinical trials reinforcing its leadership position in the mental health sector.
See More
BrainsWay to Present at 25th Annual Needham Virtual Healthcare Conference
- Conference Presentation: BrainsWay will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 8:45 AM ET, showcasing its innovative technologies in mental health, which is expected to attract investor and industry attention.
- Technological Leadership: As a global leader in noninvasive neurostimulation treatments, BrainsWay's Deep TMS™ platform has received three FDA clearances, demonstrating clinical efficacy in treating major depressive disorder, obsessive-compulsive disorder, and smoking addiction, further solidifying its market position.
- Clinical Research Advancements: The company is conducting multiple clinical trials to explore the applications of Deep TMS in various psychiatric, neurological, and addiction disorders, aiming to expand its treatment indications and improve patient quality of life.
- Global Impact: Founded in 2003, BrainsWay is committed to increasing global awareness and access to Deep TMS, driving scientific advancements in mental health treatment and showcasing its leadership in the industry.
See More
BrainsWay Completes $6 Million Investment in Neurolief Following FDA Approval
- Strategic Investment Completed: BrainsWay has finalized a $6 million milestone-based convertible loan to Neurolief, triggered by the recent FDA approval of the Proliv™Rx system, demonstrating the company's ongoing commitment to investing in mental health treatments.
- Market Expansion Potential: Proliv™Rx, designed for treatment-resistant major depressive disorder, is expected to broaden BrainsWay's total addressable market and create synergistic opportunities with its in-clinic Deep TMS™ technology, enhancing competitive positioning.
- Commercialization Progress: Following FDA approval, Neurolief has begun scaling its commercial operations and established a clear pathway into the VA health system through collaboration with the Veterans Affairs, significantly improving product market penetration.
- Future Investment Opportunities: The strategic investment agreement includes potential additional funding of up to $5 million in equity upon Neurolief achieving defined revenue targets, reflecting BrainsWay's confidence and commitment to future growth.
See More
BRAINSWAY FINALIZES $6 MILLION MILESTONE-BASED INVESTMENT IN NEUROLIEF LTD. AFTER FDA APPROVAL OF PROLIV™RX SYSTEM FOR MDD
Investment Announcement: Brainway has completed an additional investment of $6 million in NeuroLife Ltd., based in Milestone, indicating strong confidence in the company's potential.
Regulatory Approval: This investment follows the FDA's approval of the Proliv™ RX system for MDD, which is expected to enhance the company's market position and product offerings.
See More
Major Averages Decline Amid Oil Price Volatility
- Market Impact from Oil Prices: The major averages, including the Dow, fell over 400 points as oil prices surged above $100 earlier in the week, reflecting traders' concerns over volatile energy prices and geopolitical tensions in the Middle East.
- IEA's Strategic Release: The International Energy Agency's decision to release approximately 400 million barrels from strategic reserves aims to stabilize energy markets following supply shocks due to conflicts, which could help mitigate extreme oil price fluctuations.
- Inflation Data Reaction: Recent inflation data showed a 0.3% month-over-month increase in the consumer price index and a 2.4% year-over-year rise, both aligning with consensus expectations, indicating persistent inflationary pressures that may influence future monetary policy decisions.
- Escalating Geopolitical Risks: U.S. forces sunk several Iranian ships near the Strait of Hormuz, heightening the fragility of global energy supply routes and contributing to unstable market sentiment, prompting investors to adopt a cautious stance regarding future market movements.
See More
Wall Street Analysts Adjust MU Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on MU stock, indicating a shift in market sentiment, although specific rating changes were not detailed in the report.
- Increased Market Attention: As analysts focus more on MU stock, investors may reassess their investment strategies, potentially impacting the stock's market performance and price volatility.
- Impact of Rating Changes: Changes in analyst ratings typically have a direct effect on investor confidence, which could lead to increased buying or selling pressure on MU stock, thereby influencing its short-term price movements.
- Information Transparency: Despite the lack of specific rating change details, the market remains highly attentive to analysts' views, reflecting potential uncertainty regarding MU's future performance.
See More
BrainsWay Advances TMS Treatment Coverage Policy Changes
- Policy Update: In late 2025, Optum/United Behavioral Health updated its TMS clinical policy to allow psychiatric mental health nurse practitioners to administer TMS therapy in states granting full practice authority, covering approximately 34.8 million lives and significantly broadening the pool of qualified clinicians.
- Market Demand: With the increasing shortage of psychiatrists in the U.S., BrainsWay believes that expanding the role of nurse practitioners in TMS therapy will improve patient access and reduce wait times, enabling more patients to benefit from clinically proven non-pharmacologic treatment options.
- Broad Support: In addition to Optum, multiple U.S. commercial payers and government payers, including the Department of Veterans Affairs and TRICARE West, have adopted similar coverage policies, further enhancing the role of nurse practitioners in TMS care while complying with applicable policy and regulatory frameworks.
- Technological Advantage: BrainsWay's Deep TMS™ platform technology has received FDA clearance for three indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction, with ongoing clinical trials reinforcing its leadership position in the mental health sector.
See More
BrainsWay to Present at 25th Annual Needham Virtual Healthcare Conference
- Conference Presentation: BrainsWay will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 8:45 AM ET, showcasing its innovative technologies in mental health, which is expected to attract investor and industry attention.
- Technological Leadership: As a global leader in noninvasive neurostimulation treatments, BrainsWay's Deep TMS™ platform has received three FDA clearances, demonstrating clinical efficacy in treating major depressive disorder, obsessive-compulsive disorder, and smoking addiction, further solidifying its market position.
- Clinical Research Advancements: The company is conducting multiple clinical trials to explore the applications of Deep TMS in various psychiatric, neurological, and addiction disorders, aiming to expand its treatment indications and improve patient quality of life.
- Global Impact: Founded in 2003, BrainsWay is committed to increasing global awareness and access to Deep TMS, driving scientific advancements in mental health treatment and showcasing its leadership in the industry.
See More
BrainsWay Completes $6 Million Investment in Neurolief Following FDA Approval
- Strategic Investment Completed: BrainsWay has finalized a $6 million milestone-based convertible loan to Neurolief, triggered by the recent FDA approval of the Proliv™Rx system, demonstrating the company's ongoing commitment to investing in mental health treatments.
- Market Expansion Potential: Proliv™Rx, designed for treatment-resistant major depressive disorder, is expected to broaden BrainsWay's total addressable market and create synergistic opportunities with its in-clinic Deep TMS™ technology, enhancing competitive positioning.
- Commercialization Progress: Following FDA approval, Neurolief has begun scaling its commercial operations and established a clear pathway into the VA health system through collaboration with the Veterans Affairs, significantly improving product market penetration.
- Future Investment Opportunities: The strategic investment agreement includes potential additional funding of up to $5 million in equity upon Neurolief achieving defined revenue targets, reflecting BrainsWay's confidence and commitment to future growth.
See More
BRAINSWAY FINALIZES $6 MILLION MILESTONE-BASED INVESTMENT IN NEUROLIEF LTD. AFTER FDA APPROVAL OF PROLIV™RX SYSTEM FOR MDD
Investment Announcement: Brainway has completed an additional investment of $6 million in NeuroLife Ltd., based in Milestone, indicating strong confidence in the company's potential.
Regulatory Approval: This investment follows the FDA's approval of the Proliv™ RX system for MDD, which is expected to enhance the company's market position and product offerings.
See More
Major Averages Decline Amid Oil Price Volatility
- Market Impact from Oil Prices: The major averages, including the Dow, fell over 400 points as oil prices surged above $100 earlier in the week, reflecting traders' concerns over volatile energy prices and geopolitical tensions in the Middle East.
- IEA's Strategic Release: The International Energy Agency's decision to release approximately 400 million barrels from strategic reserves aims to stabilize energy markets following supply shocks due to conflicts, which could help mitigate extreme oil price fluctuations.
- Inflation Data Reaction: Recent inflation data showed a 0.3% month-over-month increase in the consumer price index and a 2.4% year-over-year rise, both aligning with consensus expectations, indicating persistent inflationary pressures that may influence future monetary policy decisions.
- Escalating Geopolitical Risks: U.S. forces sunk several Iranian ships near the Strait of Hormuz, heightening the fragility of global energy supply routes and contributing to unstable market sentiment, prompting investors to adopt a cautious stance regarding future market movements.
See More
Wall Street Analysts Adjust MU Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on MU stock, indicating a shift in market sentiment, although specific rating changes were not detailed in the report.
- Increased Market Attention: As analysts focus more on MU stock, investors may reassess their investment strategies, potentially impacting the stock's market performance and price volatility.
- Impact of Rating Changes: Changes in analyst ratings typically have a direct effect on investor confidence, which could lead to increased buying or selling pressure on MU stock, thereby influencing its short-term price movements.
- Information Transparency: Despite the lack of specific rating change details, the market remains highly attentive to analysts' views, reflecting potential uncertainty regarding MU's future performance.
See More
